Evidence map›Paper›PMID 35171945›Full record

ArticlePloS one2022

Direct-from-specimen microbial growth inhibition spectrums under antibiotic exposure and comparison to conventional antimicrobial susceptibility testing.

Jade Chen, Su Su Soe San, Amelia Kung, Michael Tomasek, Dakai Liu, William Rodgers, Vincent Gau

Abstract readComparative Study
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jade ChenGeneFluidics, Los Angeles, California, United States of America.
Su Su Soe SanGeneFluidics, Los Angeles, California, United States of America.
Amelia KungGeneFluidics, Los Angeles, California, United States of America.
Michael TomasekGeneFluidics, Los Angeles, California, United States of America.
Dakai LiuDepartment of Pathology and Clinical Laboratories, New York-Presbyterian Queens, Flushing, New York, United States of America.
William RodgersDepartment of Pathology and Clinical Laboratories, New York-Presbyterian Queens, Flushing, New York, United States of America.
Vincent GauGeneFluidics, Los Angeles, California, United States of America.ORCID 0000-0002-1948-0310

Funding

Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU SettingsR44HD084033 · NICHD · GENEFLUIDICS, INC. · PI GAU, VINCENT JEN-JR · 2015 to 2021
$4.6M
A fully integrated CentriFluidic system for direct bloodstream infection PID/ASTR01AI117059 · NIAID · GENEFLUIDICS, INC. · PI GAU, VINCENT JEN-JR · 2015 to 2019
$3.6M
NIAID NIH HHS R01 AI117059NICHD NIH HHS R44 HD084033
6 · The paper itself

Abstract

Increasing global travel and changes in the environment may escalate the frequency of contact with a natural host carrying an infection and, therefore, increase our chances of encountering microorganisms previously unknown to humans. During an emergency, the etiology of infection may be unknown at the time of patient treatment. The existing local or global Antimicrobial Stewardship Programs may not be fully prepared for emerging/re-emerging infectious disease outbreaks, especially if they are caused by an unknown organism, engineered bioterrorist attack, or rapidly evolving superbug. We demonstrate an antimicrobial efficacy profiling method that can be performed in hours directly from clinical urine specimens. The antimicrobial potency was determined by the level of microbial growth inhibition and compared to conventional antimicrobial susceptibility testing results. The oligonucleotide probe pairs on the sensors were designed to target Gram-negative bacteria, specifically Enterobacterales and Pseudomonas aeruginosa. A pilot study of 10 remnant clinical specimens from the Clinical Laboratory Improvement Amendments-certified labs of New York-Presbyterian Queens was conducted, and only one sample was not detected by the probes. The remaining nine samples agreed with reference AST methods (Vitek and broth microdilution), resulting in 100% categorical agreement. In a separate feasibility study, we evaluated a dual-kinetic response approach, in which we inoculated two antibiotic stripwells containing the same antimicrobial concentrations with clinical specimens at the original concentration (1x) and at a 10-fold dilution (0.1x) to cover a broader range of microbiological responses. The combined categorical susceptibility reporting of 12 contrived urine specimens was 100% for ciprofloxacin, gentamicin, and meropenem over a range of microbial loads from 105 to 108 CFU/mL.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial InfectionsHumansMicrobial Sensitivity TestsPilot ProjectsRNA, BacterialAnti-Bacterial AgentsRNA, Bacterial

Identifiers

PMID35171945
PMCPMC8849476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.